A Novel Gene Mutation of PIK3R1EY451delinsD in Breast Cancer with the Resistance to HER2-targeted Therapy

Kainan Wang¹, Xuelu Li¹, and Man Li²

¹The Second Hospital of Dalian Medical University
²Affiliation not available

October 16, 2020

Abstract

Previously, little is known about the relationship between the PIK3R1 mutation status and the resistance to HER2-targeted therapies. Herein, we report a HER2-positive breast cancer patient with PIK3R1EY451delinsD showed resistance to HER2-targeted therapy, and adding everolimus to the treatment of trastuzumab and carboplatin achieved better effect.

Introduction

HER2-positive breast cancer occurs in approximately 20% of all breast cancers, and HER2-targeted therapies, such as trastuzumab and lapatinib, have shown encouraging efficacy in HER2-positive breast cancer among the adjuvant and advanced disease settings. However, more than 50% HER2-positive breast cancer patients are inevitable to generate resistance to the anti-HER2 therapy ultimately. The PI3K/AKT pathway is one of the main downstream signaling pathways of HER2, and therefore the activation of the PI3K signaling pathway associates with resistance to HER2-targeted treatments. There is less research that reported the correlation between PIK3R1 mutation status and the resistance to HER2-targeted therapy in breast cancer. PIK3R1 mutations are only found in a small subset (1.8%, 87/4602, TCGA_all breast cancer studies) of breast cancers. Intriguingly, PIK3R1 mutations were more prevalent (17%, 25/147, FUSCC) in the Chinese cohort. Here we describe a HER2-positive breast cancer patient harboring PIK3R1EY451delinsD who developed resistance to HER2-targeted therapy. This provides a novel clue that PIK3R1EY451delinsD mutation might be clinically useful to choose the treatment option of everolimus for HER2 positive breast cancer.

We present the following case in accordance with the CARE reporting checklist.

Case report

We showed that a 52-year-old HER2-positive breast cancer patient underwent left breast modified radical mastectomy, and was diagnosed in December 2014 with left pT1N2M0, which immunological histological chemistry (IHC) confirmed ER-negative, PR-negative, HER2-positive 3+ (FISH+), Ki67 50%. She was then treated with 8-cycles of doxorubicin/cyclophosphamide followed by paclitaxel plus trastuzumab (AC-TH) and radiotherapy (DT) (Figure 1A). However, the PET-CT scan revealed lung metastases in January 2015. Subsequently, the patient received 4-cycles of gemcitabine/capecitabine /trastuzumab (G+X+H) and approximately ten months of lapatinib/capecitabine /trastuzumab (G+X+H) and (L+Cap) (Figure 1A), but both options achieved progressive disease (PD) as assessed by computed tomography (CT) scans using the RECIST criteria (1.1). In December 2016, metastases appeared in many organs of the body, including liver, lung and brain. To ease the neurological symptoms, the patient received the whole brain radiation therapy (WBRT) and 2-cycles of trastuzumab/avelbline (H+NVB) for metastatic disease. Disappointingly, the patient continuously progressed (Figure 1A).
Looking forward to identify other therapeutic options, the archived primary breast tumor tissue and the peripheral blood samples were collected for 425 cancer-related genes sequencing (Geneseeq, Nanjing, China) (Figure 1B), which showed ERBB2 magnification consistent with the result of HER2-positive FISH. Intriguingly, the PIK3R1 p.E451delinsD (c.1352_1354delAAT) and TP53 p.V173M (c.G517A) mutations were also detected at the high allele frequency (Figure 1B). Due to the identification of the PIK3R1 mutation and considering the increased PI3K pathway activity, we thought that the combination treatment of trastuzumab and everolimus (mTOR inhibitor) was worth applying. Therefore, the patient began the fourth-line treatment, everolimus was given combining with trastuzumab and carboplatin (H+EVER+CBP) for eight cycles (Figure 1A). After eight cycles of everolimus containing regimen, CT and MRI scans revealed the decreased lung metastasis and the stable liver lesions (Figure 1A). A peripheral blood sample collected again after eight cycles was profiled using the Geneseeq ctDNA assay, which revealed the same PIK3R1 p.E451delinsD mutation along with the persistent brain metastasis growth (Figure 1). Unfortunately, the H+EVER+CBP therapy could not block the intracranial tumor growth and the patient died shortly thereafter.

Discussion
Trastuzumab and Lapatinib have been the mainstays of anti-HER2 treatment in breast cancer. While they showed superior efficacy in subsets of primary and metastatic HER2-positive breast cancers, therapeutic resistance to HER2-targeted therapy remains an important clinical problem. Expression of mutant PIK3R1 in endometrial cancer, malignant glioma and breast cancer cell lines is associated with activation of PI3K downstream signaling. However, the clinical significance of PIK3R1 mutations in HER2-positive breast cancer patients is less well understood and needs further investigation. For the first time, we reported a case of a 52-year-old HER2-positive breast cancer patient with a novel PIK3R1 E451delinsD who developed resistance to HER2-targeted therapies. Strikingly, the combined use of trastuzumab and everolimus overcame the resistance in this case harboring PIK3R1 E451delinsD.

The precise knowledge of the genomic alterations present in cancer is critical to select the optimal treatment for each patient, so monitoring the impact of individual oncogenic alterations on lesion specific responses is indispensable. Cheung et al. and Urick et al. reported that the PIK3R1 indels (E439del, H450-E451del, Y463-L466del, R574fs, T576del, R574-T576del) have shown to be oncogenic and led to increased levels of p-AKT in endometrial cancer. Quayle et al. demonstrated that three PIK3R1 indels (DKRMNS560del, R574fs, T576del) with the strongest activities increased P110α kinase activity in the in vitro kinase assay in malignant glioma. Cheung et al. uncovered that the PIK3R1 R348* and L370fs truncations were localized to the nucleus, where they facilitated abnormal pathway activation. Thorpe et al. and their colleagues found that the genetic ablation of PIK3R1 accelerated a mouse model of HER2/neu-driven breast cancer.

Chen et al. provided a landscape of PIK3R1 mutations in 149 Chinese breast cancer patients, and reported that PIK3R1 mutations were prevalent (25 tumors, 17%) in this Chinese cohort. They also confirmed when normal mammary epithelial cell line MCF10A overexpressing exogenous PIK3R1 mutations were grown in the absence of EGF, the levels of pAKTSer473 were slightly higher. Together, there is an increasing number of evidence that PIK3R1 mutations activate the PI3K signaling pathway and display oncogenic properties.

By analyzing the cBioPortal database, there is a huge difference of frequency range of PIK3R1 alterations among types of cancer from more than 30% to less than 2% (Figure 2A). It is also worth noting that there are about 31% PIK3R1 mutations (Uterine_TCGA PanCan, Figure 2A) that frequently occur in uterine corpus endometrial carcinoma. Future PIK3R1 mutational location analysis that covers all mutations is shown as Figure 2B, including 6539 patients and 1690 mutations. In addition, we also summary characteristics of eleven patients with the same E541_Y542del from cBioPortal (Figure 2C), but PIK3R1 E451delinsD is a rare mutant form with little prior knowledge in breast cancer patients. To better display the result of PIK3R1 mutations, we showed that genomic characterization of PIK3R1 in breast cancer cohorts (Figure 2D and 2E). PIK3R1 mutations are only found in a small subset of breast cancers including HER2 positive subtype (Figure 2E). In contrast, PIK3R1 mutations (not including
PIK3R1<sub>EY451delinsD</sub> are prevalent (25 tumors, 17%) in Chinese breast cancer patients<sup>6</sup>. This is the first report representing PIK3R1<sub>EY451delinsD</sub> in breast cancer.

This novel PIK3R1<sub>EY451delinsD</sub> confers resistance to trastuzumab and lapatinib in HER2-positive breast cancer. Fortunately, this case supports the combined use of trastuzumab and everolimus after failure of previous targeted therapies in HER2-positive breast cancer patient harboring PIK3R1<sub>EY451delinsD</sub>. However, brain metastasis was very tricky to treat in clinical, and we needed more effective drugs to cross the blood-brain barrier. We believe that PIK3R1 alterations can be clinically useful to predict the treatment response for HER2-targeted treatment. In the future, functional PIK3R1 alterations should be incorporated in clinical trials to evaluate treatment response of targeted therapies in HER2-positive breast cancer.

Preclinical studies have demonstrated that breast cancer cell lines harboring PIK3R1 mutants or loss of p85α (encoded by PIK3R1 gene) activate the PI3K/AKT signaling pathway<sup>6, 12</sup>. However, whether PIK3R1 mutation status confers resistance to HER2-targeted therapies still awaits testing in HER2 positive breast cancer patients. Our case validated PIK3R1<sub>EY451delinsD</sub> as a potential mechanism of resistance to HER2-targeted inhibition, and suggested that PIK3R1 alterations may also be clinically useful to stratify the treatment option for HER2-targeted therapies or in combination with everolimus treatment.

Abbreviations

ctDNA: circulating tumor DNA
AF: allele frequency.
AC: doxorubicin/cyclophosphamide
TH: paclitaxel/trastuzumab
DT: radiotherapy
G+X+H: gemcitabine/xeloda/trastuzumab
L+Cap: Lapatinib/capecitabine
WBRT: whole brain radiation therapy
NVB: navelbine
EVE: everolimus
CBP: Carboplatin
FUSCC: Fudan University Shanghai Cancer Center
PI3K: phosphatidylinositol-3-kinase

Acknowledgments

We would like to thank Qiwei Pan for their expert technical assistance and helpful comments.

Author contribution

X. L. and K.W. participated in clinical therapy and statistical analysis. X.L., K.W. and M.L. wrote the manuscript. M.L. and Z.Z. revised the manuscript. All authors read and approved the final manuscript.

Conflict of Interest

The authors declare no conflict of interest.

Disclosure

Funding: This work was supported by the National Natural Science Foundation of China (NO.81872756 to Man Li).
Ethical Statement: All of the intended procedures in the present study, including the use of specimens from human subjects, were approved with the written informed consent of the patient. The experimental protocol was approved by the Dalian Medical University Ethics Committee.

References

Figure Legends
Figure 1. Basic Information of the patient.
(A) The treatment timelines, and images of brain, liver and lung metastases. AC, doxorubicin/cyclophosphamide; TH, paclitaxel/trastuzumab; DT, radiotherapy; G+X+H, gemcitabine/xeloda/trastuzumab; L+Cap, Lapatinib/capecitabine; WBRT, whole brain radiation therapy; NVB, navelbine; EVE, everolimus; CBP, Carboplatin. (B) Somatic mutations of ctDNA detected by 425 cancer-related genes sequencing. AF, allele frequency.

Figure 2. Characteristics of PIK3R1 mutations from cBioPortal.
The data is analyzed by www.cbioportal.org in all cancer types (A, B) and the breast cancer cohorts (D, E). (C) Malignant tumor patients with PIK3R1E541,Y542del are summarized in the table. Location
of PIK3R1<sup>E541_Y542del</sup> is indicated in Figure 2B (red arrow).

**Figure 1**

**A. Treatment timeline**

<table>
<thead>
<tr>
<th>Year</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease</td>
<td>Left breast modified radical mastectomy</td>
<td>Lung Metastasis</td>
<td>ctDNA</td>
<td>ctDNA</td>
<td>ctDNA</td>
</tr>
<tr>
<td>Treatment</td>
<td>AC-TH (8)</td>
<td>ST</td>
<td>G+X+H (4)</td>
<td>L+Cap</td>
<td>WBRT</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Year</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease</td>
<td>Left IDC</td>
<td>Brain metastasis, Lung metastasis, Bone metastasis</td>
<td>Liquid biopsy</td>
<td>Liquid biopsy</td>
<td>Liquid biopsy</td>
</tr>
</tbody>
</table>

**B. Mutational profiling of this breast cancer case.**

<table>
<thead>
<tr>
<th>Gene</th>
<th>PMT (AF)</th>
<th>1&lt;sup&gt;st&lt;/sup&gt; (2017 June)</th>
<th>2&lt;sup&gt;nd&lt;/sup&gt; (2018 Jan)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIK3R1 p.EY451delinsD(c.1352_1354delAAT)</td>
<td>13.3%</td>
<td>21.8%</td>
<td>19.6%</td>
</tr>
<tr>
<td>TP53 p.V173M (c.G517A)</td>
<td>37.60%</td>
<td>46.20%</td>
<td>49.30%</td>
</tr>
<tr>
<td>ERBB2 (Copy-Number Variation)</td>
<td>8.8</td>
<td>6.3</td>
<td>5.1</td>
</tr>
</tbody>
</table>
Alteration Frequency

A. PIK3R1

Mutation Frequency: 2.2%

B. Alteration Frequency

C. PIK3R1 Mutation Frequency: 1.8%

<table>
<thead>
<tr>
<th>Case Number</th>
<th>Cancer Type</th>
<th>Protein Change</th>
<th>Allele Freq</th>
<th>Mutation in sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>TCGA-CS-5394-01</td>
<td>Anaplastic Astrocytoma</td>
<td>E451_Y452del</td>
<td>0.44</td>
<td>20</td>
</tr>
<tr>
<td>TCGA-AG-3726-01</td>
<td>Rectal Adenocarcinoma</td>
<td>E451_Y452del</td>
<td>0.49</td>
<td>140</td>
</tr>
<tr>
<td>TCGA-A5-A0GQ-01</td>
<td>Uterine Endometrial Carcinoma</td>
<td>E451_Y452del</td>
<td>0.14</td>
<td>57</td>
</tr>
<tr>
<td>TCGA-BS-A1T6-01</td>
<td>Uterine Endometrial Carcinoma</td>
<td>E451_Y452del</td>
<td>0.26</td>
<td>8057</td>
</tr>
<tr>
<td>TCGA-CS-5394-01</td>
<td>Diffuse Glioma</td>
<td>E451_Y452del</td>
<td>0.43</td>
<td>19</td>
</tr>
<tr>
<td>P-0011284-T01-IM5</td>
<td>Esophageal Adenocarcinoma</td>
<td>E451_Y452del</td>
<td>0.14</td>
<td>7</td>
</tr>
<tr>
<td>P-0021892-T01-B0</td>
<td>Lung Squamous Cell Carcinoma</td>
<td>E451_Y452del</td>
<td>–</td>
<td>11</td>
</tr>
<tr>
<td>P-0021900-T01-B0</td>
<td>Lung Squamous Cell Carcinoma</td>
<td>E451_Y452del</td>
<td>–</td>
<td>8</td>
</tr>
<tr>
<td>P-0022232-T01-B0</td>
<td>Glioblastoma Multiforme</td>
<td>E451_Y452del</td>
<td>–</td>
<td>3</td>
</tr>
<tr>
<td>SJHGG024-R</td>
<td>B-Lymphoblastic Leukemia</td>
<td>E451_Y452del</td>
<td>–</td>
<td>25</td>
</tr>
<tr>
<td>TCGA-CS-5394-01</td>
<td>Diffuse Glioma</td>
<td>E451_Y452del</td>
<td>0.43</td>
<td>19</td>
</tr>
<tr>
<td>P-0001680-T02-IM3</td>
<td>Lung Squamous Cell Carcinoma</td>
<td>E451_Y452del</td>
<td>–</td>
<td>8</td>
</tr>
<tr>
<td>P-0002022-T01-IM3</td>
<td>Glioblastoma Multiforme</td>
<td>E451_Y452del</td>
<td>–</td>
<td>3</td>
</tr>
<tr>
<td>P-0003600-T01-IM5</td>
<td>Glioblastoma Multiforme</td>
<td>E451_Y452del</td>
<td>–</td>
<td>3</td>
</tr>
</tbody>
</table>

Figure 2